New targeted drug hopes to shrink Hard-to-Treat cancers
NCT ID NCT07629960
First seen Jun 07, 2026 · Last updated Jun 19, 2026 · Updated 2 times
Summary
This study tests a new drug called BLU-924 in people with advanced pancreatic, lung, or colorectal cancer that has a specific KRAS gene change. The drug aims to block the cancer's growth signals. The trial will check safety, the right dose, and whether the drug shrinks tumors, alone or with other treatments. About 265 adults with these cancers can join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Next Oncology Virginia Cancer Specialist
RECRUITINGFairfax, Virginia, 22031, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.